Tumor Profiling Market Size & Growth Forecast 2026–2035, By Segments (Technique), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Tumor Profiling Market size was assessed at USD 12.99 Billion in 2025 and is poised to grow at a 10.2% CAGR between 2026 and 2035, reaching USD 34.31 Billion by 2035. The industry revenue for 2026 is calculated at USD 14.17 billion.
Get more details on this report
Request Free Sample ReportTumor Profiling Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 38.90% market share in 2025, driven by advanced oncology diagnostics infrastructure, broad genomic testing availability, and strong integration of molecular profiling into clinical care.
- Asia Pacific is expected to expand at an 11.42% CAGR as molecular testing access improves, laboratory capabilities expand, and profiling becomes more widely used for cancer diagnosis and treatment planning.
Segment Momentum
- Genomics leads with a 40.28% share because it identifies tumor mutations and directly supports targeted therapy decisions, making it central to established oncology diagnostic workflows.
- Epigenetics is gaining momentum as it reveals gene regulation and tumor heterogeneity insights beyond genomics, supporting deeper biological understanding in advanced profiling applications.
Market Expansion Drivers
- Rising cancer incidence driving demand for precision oncology-based personalized treatment selection.
- Next-generation sequencing advancements enabling faster, more accurate genomic tumor analysis.
- Expansion of AI-driven bioinformatics platforms improving tumor data interpretation and clinical workflows.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Major companies in the tumor profiling market include Illumina, Inc. (United States), QIAGEN N.V. (Netherlands), Exact Sciences Corporation (United States), Guardant Health, Inc. (United States), Foundation Medicine, Inc. (United States), NeoGenomics, Inc. (United States), Bruker Corporation (United States), Veracyte, Inc. (United States), Thermo Fisher Scientific Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As cancer diagnoses increase, treatment pathways are becoming more dependent on molecular characterization rather than tumor site alone, which is driving demand for the tumor profiling market. Oncologists and cancer centers are using profiling results to identify actionable mutations, stratify patients for targeted therapies, and avoid ineffective regimens that add cost and toxicity without improving outcomes. This trend makes tumor profiling a more routine step in clinical decision-making, especially in cases where therapy selection, resistance monitoring, or eligibility for biomarker-linked treatments depends on genomic and proteomic evidence.
Next-generation sequencing advancements enabling faster, more accurate genomic tumor analysis
Improved next-generation sequencing workflows are reducing turnaround times while expanding the number and quality of detectable alterations, strengthening market development in the tumor profiling market. Higher sensitivity and broader panel coverage allow laboratories to detect clinically relevant mutations, fusions, copy number changes, and other biomarkers from limited tissue samples, which is critical in oncology settings where biopsy material is often scarce. As testing becomes more reliable and operationally efficient, hospitals, diagnostic labs, and oncology networks are more willing to integrate comprehensive profiling into standard care pathways rather than reserving it for complex or late-stage cases.
Expansion of AI-driven bioinformatics platforms improving tumor data interpretation and clinical workflows
The expansion of AI-driven bioinformatics platforms is influencing market adoption by turning complex sequencing output into clinically usable insights at a scale that manual interpretation cannot match. In the tumor profiling market, these platforms help prioritize variants, connect findings to therapy options and trial matching, and reduce the reporting burden on molecular pathologists and oncology teams. That practical improvement in workflow efficiency is especially important as test volumes rise and biomarker panels become more complex, making AI-enabled interpretation a key factor supporting broader use of tumor profiling in routine cancer care.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising cancer incidence driving demand for precision oncology-based personalized treatment selection | 2.20% | High | North America, Europe | High | Near Term |
| Next-generation sequencing advancements enabling faster, more accurate genomic tumor analysis | 2.00% | High | North America, Asia Pacific | High | Near Term |
| Expansion of AI-driven bioinformatics platforms improving tumor data interpretation and clinical workflows | 1.60% | Moderate | Asia Pacific, North America | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 38.90% share of the tumor profiling market in 2025, supported by the region’s established oncology diagnostics infrastructure, broad availability of advanced genomic testing platforms, and high integration of molecular profiling into routine cancer care. Market leadership is reinforced by the practical use of tumor profiling across hospitals, specialty cancer centers, and reference laboratories, where testing is increasingly embedded in treatment selection, biomarker identification, and clinical decision-making. The region’s position is also supported by strong adoption of precision medicine workflows and the presence of companies actively commercializing profiling technologies across research and clinical settings.
Asia Pacific is projected to expand at an 11.42% CAGR over the forecast period, with the tumor profiling market gaining momentum as cancer diagnostics capacity broadens and access to molecular testing improves across major healthcare systems. Growth is being impelled by rising use of genomic and companion diagnostic approaches in oncology practice, alongside increasing deployment of advanced laboratory capabilities in urban and high-volume care centers. As regional providers continue incorporating profiling tools into cancer detection and therapy planning pathways, adoption is accelerating in ways that directly support higher test volumes and wider clinical use.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Molecular Diagnostics IntegrationGermany emphasizes tumor profiling as part of precision oncology programs within hospitals and specialized diagnostic laboratories. Clinical adoption is supported by demand for standardized testing workflows and high-quality genomic analysis capabilities.
France 🇫🇷
Personalized Treatment SupportFrance is advancing tumor profiling by incorporating comprehensive molecular testing into multidisciplinary cancer care pathways. Clinical stakeholders focus on improving access to biomarker analysis that guides targeted therapeutic decisions across oncology specialties.
Italy 🇮🇹
Oncology Diagnostics DevelopmentItaly is expanding tumor profiling services through collaboration between hospitals, research institutions, and diagnostic laboratories. Healthcare providers increasingly rely on molecular profiling to strengthen personalized cancer treatment strategies and clinical evaluation.
Japan 🇯🇵
Clinical Genomics AdoptionJapan is strengthening tumor profiling through greater integration of molecular diagnostics into oncology practice. Healthcare institutions prioritize accurate biomarker identification that supports individualized treatment planning and improved clinical decision processes.
South Korea 🇰🇷
Advanced Cancer TestingSouth Korea continues expanding tumor profiling capabilities through investment in precision medicine and advanced laboratory infrastructure. Providers increasingly adopt next-generation sequencing platforms to improve personalized oncology care and biomarker-driven treatment selection.
United States 🇺🇸
Precision Oncology ExpansionThe U.S. tumor profiling market continues to expand through wider adoption of genomic testing in personalized cancer treatment. Healthcare providers increasingly integrate comprehensive molecular profiling into clinical decision-making and targeted therapy selection.
Segment Leadership and Growth Trends
Tumor Profiling Market Share (%), Technique, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportWithin the tumor profiling market, Genomics held a 40.28% share in 2025, making it the leading technique segment. This leadership is maintained through the central role of genomic analysis in identifying tumor-specific mutations, guiding targeted therapy selection, and supporting routine oncology decision-making. Genomics remains deeply embedded in tumor profiling workflows because it provides directly actionable molecular information that clinicians and laboratories can integrate into established diagnostic and treatment pathways.
Epigenetics is emerging as the fastest-growing technique in the tumor profiling market as demand rises for deeper insight beyond sequence-level alterations. Its momentum is being backed by the growing need to understand gene regulation, tumor heterogeneity, and disease progression patterns that may not be fully captured through genomics alone. Compared with more established techniques, epigenetics is gaining traction because it helps expand the biological context of tumor assessment, making it increasingly relevant for advanced profiling applications.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Technique | Genomics, Proteomics, Metabolomics, Epigenetics | Genomics | Epigenetics |
Competitive Landscape and Market Positioning
1. Illumina Inc. (United States)
2. QIAGEN N.V. (Netherlands)
3. Exact Sciences Corporation (United States)
4. Guardant Health Inc. (United States)
5. Foundation Medicine Inc. (United States)
6. NeoGenomics Inc. (United States)
7. Bruker Corporation (United States)
8. Veracyte Inc. (United States)
9. Thermo Fisher Scientific Inc. (United States)
10. F. Hoffmann-La Roche Ltd (Switzerland)
Advancements in precision diagnostics are accelerating transformation in the tumor profiling market, enabling more targeted clinical decision-making. Integration of genomic and molecular analytics is improving diagnostic accuracy and treatment alignment. Collaborative frameworks across research and clinical ecosystems are enhancing innovation speed. The tumor profiling market is increasingly defined by the shift toward highly personalized oncology insights.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| ClearNote Health | Sep-25 | ClearNote Health secured $52 million in Series D financing to accelerate the commercialization of its noninvasive early cancer detection technologies. This capital infusion, combined with leadership expansion, strengthens the company’s ability to scale operations and meet the rising demand for advanced oncology diagnostics within the tumor profiling landscape. |
| Cartography Biosciences | Sep-25 | Cartography Biosciences received a strategic investment from Samsung Ventures to bolster its proprietary drug discovery platform and oncology pipeline. This partnership enhances the company’s capabilities in precision medicine by integrating advanced computational approaches with tumor profiling, supporting the development of highly targeted oncology solutions. |
| Illumina | Aug-25 | Illumina expanded its precision oncology partnership with Labcorp to co-develop and commercialize distributed NGS-based in vitro diagnostic tests. By combining their respective liquid and tissue biopsy expertise, the firms aim to increase market access to comprehensive cancer biomarker testing and standardized tumor profiling workflows. |
| Genomate Health | Aug-25 | Genomate Health acquired Oncompass Medicine to establish an expanded operational footprint in Europe and strengthen its global position. The integration of Oncompass’s precision medicine assets enhances Genomate’s computational oncology capabilities, facilitating more robust data-driven insights for personalized cancer care and tumor profiling applications. |
| Elephas Biosciences | Aug-25 | Elephas Biosciences raised $40 million in Series B-2 financing to support the commercialization of its live tumor profiling platform. The funding will be utilized to finalize launch preparations for its laboratory-developed test, which evaluates real-time patient response to immunotherapy, representing a material advancement in functional precision oncology. |
| Thermo Fisher Scientific | Aug-25 | Thermo Fisher Scientific received FDA approval for the Oncomine Dx Express Test, an NGS-based assay that serves as a companion diagnostic for sunvozertinib in non-small cell lung cancer. This regulatory milestone bolsters the company’s competitive position by providing a streamlined, rapid profiling solution for clinical precision oncology. |
| Pleno | Aug-25 | Pleno raised $25 million to advance the commercialization of its multiomics platform and the upcoming launch of the Raptor benchtop analyzer. This investment enhances the company’s ability to scale advanced molecular analysis technologies, providing a scalable infrastructure for high-throughput tumor profiling and complex genomic research. |
| Pillar Biosciences | Aug-25 | Pillar Biosciences launched oncoReveal Lymphoid, an NGS-based assay designed for the rapid profiling of lymphoid malignancies. This addition to the company’s oncology portfolio provides molecular laboratories with a targeted diagnostic tool, addressing specific clinical needs in hematologic oncology and expanding the firm's reach in clinical testing markets. |
| Illumina | Aug-24 | Illumina received FDA approval for the TruSight Oncology Comprehensive, an in vitro diagnostic kit assessing over 500 genes. This tool provides critical pan-cancer companion diagnostic claims, significantly improving clinical capabilities for patient stratification and therapeutic matching through comprehensive genomic profiling. |
| QIAGEN | Jun-22 | QIAGEN launched the therascreen EGFR Plus RGQ PCR Kit to detect the C797S mutation in non-small cell lung cancer patients. By enabling the identification of specific resistance mutations via real-time PCR, the kit provides essential insights for therapy selection, demonstrating the company’s focus on advancing personalized oncology care. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Tumor Profiling Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Tumor Profiling Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the market size of tumor profiling?
What is the expected industry size of tumor profiling by 2035?
How is precision oncology influencing clinical adoption and decision-making in the tumor profiling market?
How are next-generation sequencing and AI bioinformatics improving efficiency in tumor profiling adoption?
What makes genomics the leading technique in the tumor profiling market?
Why is epigenetics emerging as the fastest-growing technique in tumor profiling?
What makes North America the leading regional market for tumor profiling?
How is Asia Pacific driving growth in the tumor profiling market?
Which organizations are considered leaders in the tumor profiling landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization